Ken Keller has been named executive vice president and chief operating officer at Spectrum Pharmaceuticals. Mr. Keller will have global responsibility for leading commercial operations, medical and clinical development and pharmaceutical operations. He has more than 20 years’ experience in the pharmaceutical industry from sales and marketing leadership to general management and joint venture leadership in several therapeutic areas, including oncology, rheumatology, dermatology and primary care.
 
Prior to joining the company, Mr. Keller spent 21 years at Amgen, most recently as vice president and general manager of the Bone Health Business Unit. Prior to that, he was responsible for the Inflammation Business Unit. While at Amgen, Mr. Keller was the marketing lead for the general manager for top selling biologic medicines Neupogen, Neulasta, Aranesp, and Enbrel.
 
“We are pleased to welcome Ken to Spectrum and believe he will be a strong asset to our management team,” said Rajesh C. Shrotriya, M.D., chairman, president and chief executive officer of Spectrum Pharmaceuticals, Inc. “Ken is a leader in marketing and product launches, having directed the commercialization programs for three of Amgen’s top five biologics in worldwide sales. As Spectrum prepares for increased sales of its current product portfolio and introductions of new products, we anticipate Ken’s experience will be invaluable.”